ArticleOncology letters2025

Azacitidine plus venetoclax for maintenance treatment in intermediate‑to‑low‑risk acute myeloid leukemia: A comparative analysis of clinical outcomes in an observational cohort.

Danyang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.